Mutation signature of adenoid cystic carcinoma: Evidence for transcriptional and epigenetic reprogramming

Journal of Clinical Investigation

Volumn 123, Issue 7, 2013, Pages 2783-2785

  Frierson, Henry F ^a   Moskaluk, Christopher A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; NUCLEAR FACTOR I; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADENOID CYSTIC CARCINOMA; APOPTOSIS; CELL ADHESION; CELL GROWTH; CHROMATIN STRUCTURE; CHROMOSOME 9; COMPARATIVE GENOMIC HYBRIDIZATION; DROSOPHILA; EPIGENETICS; GENE FUSION; GENE MUTATION; GENOMICS; KARYOTYPING; NOTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REGULATORY MECHANISM; RNA BINDING;

EID: 84879662071     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI69070     Document Type: Note

References (22)

1. Stephens PJ, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123(7):2965-2968.
2. Lloyd S, Yu JB, Wilson LD, Decker RH. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol. 2011;34(1):76-81.
3. Persson M, Andren Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106(44):18740-18744.
4. Persson M, et al. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer. 2012;51(8):805-817.
5. Bernheim A, et al. High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest. 2008;88(5):464-473. (Pubitemid 351581453)
6. Rao PH, et al. Deletion of 1p32-p36 is the most frequent genetic change and poor prognostic marker in adenoid cystic carcinoma of the salivary glands. Clin Cancer Res. 2008;14(16):5181-5187.
7. El-Rifai W, Rutherford S, Knuutila S, Frierson HF Jr, Moskaluk CA. Novel DNA copy number losses in chromosome 12q12--q13 in adenoid cystic carcinoma. Neoplasia. 2001;3(3):173-178. (Pubitemid 32747565)
8. Yu Y, Baras AS, Shirasuna K, Frierson HF Jr, Moskaluk CA. Concurrent loss of heterozygosity and copy number analysis in adenoid cystic carcinoma by SNP genotyping arrays. Lab Invest. 2007;87(5):430-443.
9. Nie Z, et al. A specificity and targeting subunit of a human SWI/SNF family-related chromatin-remodeling complex. Mol Cell Biol. 2000:20(23);8879- 8888. (Pubitemid 32248734)
10. Das C, Lucia MS, Hansen KC, Tyler JK. CBP/p300-mediated acetylation of histone H3 on lysine56. Nature. 2009;459(7259):113-117.
11. Gayther SA, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet. 2000;24(3):300-303. (Pubitemid 30132203)
12. Lan F, et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature. 2007;449(7163):689-694. (Pubitemid 47552096)
13. Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene. 2001;20(24):2991-3006. (Pubitemid 32553553)
14. Oswald F, et al. SHARP is a novel component of the Notch/RBP-J-kappa signaling pathway. EMBO J. 2002;21(20):5417-5426. (Pubitemid 35231021)
15. Sierra OL, Cheng S-L, Loewy AP, Charlton-Kachigian N, Towler DA. MINT, the Msx2 interacting nuclear matrix target, enhances Runx2-dependent activation of the osteocalcin fibroblast growth factor response element. J Biol Chem. 2004;279(31):32913-32923. (Pubitemid 39014751)
16. Ross PJ, et al. Epirubicin, cisplatin and protracted venous infusion 5-Fluorouracil chemotherapy for advanced salivary adenoid cystic carcinoma. Clin Oncol (R Coll Radiol). 2009;21(4):311-314.
17. Phuchareon J, Ohta Y, Woo JM, Eisele DW, Tetsu O. Genetic profiling reveals cross-contamination and misidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PloS One. 2009;4(6):e6040.
18. Moskaluk CA, et al. Development and characterization of xenograft model systems for adenoid cystic carcinoma. Lab Invest. 2011;91(10):1480-1490.
19. Deng Q-L, Ishii S, Sarai A. Binding site analysis of c-Myb: Screening of potential binding sites by using the mutation matrix derived from systematic binding affinity measurements. Nucl Acids Res. 1996;24(4):766-774. (Pubitemid 26085854)
20. Miglarase MR, Halaban R, Gibson NW. Regulation of fibroblast growth factor 2 expression in melanoma cells by the c-MYB proto-oncogene. Cell Growth Differ. 1997;8(11):1199-1210. (Pubitemid 27481656)
21. University of Virginia. Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma (ACC). NIH Web site. http://clinicaltrials.gov/ct2/show/NCT01524692. Updated January 15, 2013. Accessed May 14, 2013.
22. Ho AS, et al. The mutational landscape of adenoid cystic carcinoma [published online ahead of print May 19, 2013]. Nat Genet. doi:10.1038/ng.2643. Research Research